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Abstract
BACKGROUND—Hospital readmission is a significant problem for patients with complex 
chronic illnesses such as liver cirrhosis.
PURPOSE—We aimed to describe the range of readmission risk in patients with cirrhosis and 
the impact of the model for end-stage liver disease (MELD) score.
DATA SOURCES—We conducted a systematic review of studies identified in Ovid MEDLINE, 
PubMed, EMBASE, CINAHL, the Cochrane Library, Scopus, Google Scholar, and 
ClinicalTrials.gov from 2000 to May 2017.
STUDY SELECTION—We examined studies that reported early readmissions (up to 90 days) in 
patients with cirrhosis. Studies were excluded if they did not examine the association between 
readmission and at least 1 variable or intervention.
DATA EXTRACTION—Two reviewers independently extracted data on study design, setting, 
population, interventions, comparisons, and detailed information on readmissions.
DATA SYNTHESIS—Of the 1363 records reviewed, 26 studies met the inclusion and exclusion 
criteria. Of these studies, 21 were retrospective, and there was significant variation in the inclusion 
and exclusion criteria. The pooled estimate of 30-day readmissions was 26%(95% confidence 
interval [CI], 22%–30%). Few studies examined readmission preventability or the relationship 
between readmissions and social determinants of health. Reasons for readmission were highly 
variable. An increased MELD score was associated with readmissions in most studies. 
Readmission was associated with increased mortality.
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CONCLUSION—Hospital readmissions frequently occur in patients with cirrhosis and are 
associated with liver disease severity. The impact of functional and social factors on readmissions 
is unclear.
Cirrhosis is a morbid condition characterized by complications such as ascites, 
gastrointestinal bleeding, and hepatic encephalopathy. These complications frequently 
require hospitalization, which is a substantial burden to the healthcare system. In 2012, liver 
disease was responsible for nearly 250,000 admissions across the United States, costing $3 
billion.1 Despite this substantial resource utilization, outcomes remain poor, with an 
inpatient mortality of 6%. For those that survive, many experience hospital readmission.
More generally, early readmission reflects poor quality of care in the US. In 2004, 30-day 
readmissions occurred in nearly 20% of Medicare beneficiaries and costed over $17 billion.2 
In response to this problem, the Affordable Care Act established the Hospital Readmissions 
Reduction Program (HRRP), which reduces Centers for Medicare & Medicaid Services 
(CMS) payments to hospitals with excess 30-day readmissions for high-risk conditions, 
including pneumonia and heart failure.3 Heart failure, in particular, has been the subject of 
numerous studies detailing risk factors and interventions to predict and prevent readmission.
4–6
 Based on this extensive evidence, guidelines recommend disease management programs 
to reduce readmissions in this population.7 In contrast, readmission in the cirrhosis 
population has received limited attention.
We therefore conducted a systematic review aiming to examine the range of readmission risk 
noted in the literature, with a focus on the model for end-stage liver disease (MELD) score 
as a risk factor for readmission.
METHODS
Search Strategy
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
guidelines for conducting and reporting systematic reviews.8 A literature search was 
performed by a medical librarian using the following databases: Ovid MEDLINE, PubMed, 
EMBASE, CINAHL, the full Cochrane Library, Scopus, Google Scholar, and 
ClinicalTrials.gov. All the databases were searched from 2000 to May 2017. We did not 
include older reports because the review focused on contemporary care; earlier studies may 
not reflect current cirrhosis management. To ensure literature saturation, included articles’ 
reference lists were reviewed.
Search strategies were developed by combining database-specific subject headings and 
keywords for readmissions with those for cirrhosis or its complications (Supplementary 
Material). Google Scholar and ClinicalTrials.gov were searched using keywords only. All 
results were limited to the English language and those published in 2000 or later, but no 
other limits were applied.
Identified records were reviewed based on strict criteria. We excluded case reports, case 
series, reviews, editorials, letters, and meeting abstracts without final peer-reviewed 
publication. We also excluded studies of pediatric populations (age < 18 years), patients 
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without cirrhosis, and patients with liver transplants. We excluded studies in which patients 
were not hospitalized at study onset and those where the index admission was for an elective 
procedure. Because our interest was to identify factors associated with early readmission, we 
excluded studies that did not report readmissions within 90 days or those with a mean or 
median follow-up of less than 30 days. We also excluded studies that did not examine the 
association between readmission and at least 1 independent variable or intervention. 
Duplicate reports of a common sample were excluded unless the duplicate provided 
additional information, and such reports were examined together in our synthesis.
Two authors identified potentially eligible records by independently screening titles and 
abstracts. At this stage, records that did not meet the eligibility criteria were excluded, and 
the reasons for exclusion were not recorded. Records with disagreement were retained for 
full-text review. After this initial exclusion of records, the remaining full-text records were 
reviewed independently. For this full-text review, we recorded exclusion reasons and 
disagreements were resolved through discussion.
Data Collection
Data were abstracted from each study by 2 authors independently and recorded in a 
REDCap database.9 Discrepancies were resolved through discussion. We recorded study 
characteristics, including study design, setting, population (including the inclusion/exclusion 
criteria, sample size, and patient and hospitalization characteristics), interventions, and 
comparisons. To facilitate comparisons across studies, we employed validated methods to 
approximate means and standard deviations (SD).10 We recorded detailed information on 
outcomes including readmissions, preventability, independent variables, and mortality. 
Studies that focused on a single independent factor or intervention were classified as 
“focused,” while those that examined multiple factors were classified as “broad.” We used 
the Newcastle–Ottawa Scale to assess the risk of bias in each study.11 This instrument uses a 
9-point scale to gauge methodological quality based on selection, group comparability, and 
exposure/outcome assessment.
Statistical Analysis
Analyses were performed using Stata 13.1 (StataCorp LP, College Station, Texas). We 
determined the pooled proportion of patients with 30-day readmission using a random-
effects model, with the Freeman–Tukey double-arcsine transformation for meta-analysis of 
proportions.12 We investigated the heterogeneity by stratifying analyses according to 
prespecified study characteristics, including “broad” versus “focused.” However, the 
readmission risk was not different in the stratified analysis; therefore, we chose to pool the 
findings. For point estimates, 95% confidence intervals (CIs) were calculated, and a P-value 
< .05 was considered statistically significant.
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RESULTS
Search Results
The initial search yielded 1363 records, of which 173 full-text articles were assessed for 
eligibility. Twenty-seven articles representing 26 studies of 180,049 patients were included 
(Figure 1).13–39
Study Characteristics
Two studies were performed in Australia, 4 in Europe, and the remainder in North America. 
Twenty one of the 26 studies were retrospective cohort studies (Table 1). Twenty studies 
were single-center studies (of which half were performed at transplant centers), and 4 of the 
6 multicenter studies were based on administrative data with large samples (173,254 
patients). The inclusion/exclusion criteria varied widely (Supplementary Material). Some 
studies only included patients admitted for specific cirrhosis complications, while others 
included those admitted for any reason. Two studies excluded patients admitted in the prior 
30 days, and 6 excluded patients discharged to hospice. The mean risk of bias score was 7.5 
(SD 1.3) out of a possible 9 points, with most lacking an adequate description of follow-up 
and several lacking adjustment for confounders.
The mean age of patients ranged from 53 to 65 years, and males comprised 56%–78% 
(except for 4 Veterans Affairs studies). The mean MELD score ranged from 12 to 23. 
Hepatitis C accounted for 14%–100% of cirrhosis, alcohol accounted for 25%–67%, and 
nonalcoholic fatty liver disease accounted for 0%–20%. Hepatocellular carcinoma was 
present in 6%–30% of the patients. Reasons for the index admission varied widely and were 
dependent on the inclusion/exclusion criteria.
Outcomes
Thirty-day readmissions ranged from 10% to 50%, with a pooled estimate of 26% (95% CI, 
22%–30%; Figure 2). Five studies reported 90-day readmissions, ranging from 21% to 71%.
29,31,33,35,36
 Only 4 of the 20 single-center studies captured readmissions at centers aside 
from the index admission hospital. Two studies assessed readmission preventability: 1 
through independent chart review by 2 physicians (22% preventable), the other based on the 
judgement of 1 physician (37%).16,26 Reasons for readmission were reported in 12 studies 
and were highly variable: hepatic encephalopathy in 6%–100%, ascites/volume overload in 
2%–38%, and decompensated liver disease (without further elaboration) in 25%–100%. The 
studies that focused on single risk factors or interventions reported a wide range of possible 
readmission risk factors, ranging from biomarkers to clinical processes of care. Although 
multiple putative risk factors were reported, few conclusions can be drawn due to the 
heterogeneity in the findings. In 5 studies, 90-day mortality was reported and ranged from 
10.3% to 18.6%. The relationship between readmission and subsequent mortality was 
examined in 5 studies, and all were statistically significant.14,16,20,33,38
Readmission and MELD
The MELD score was examined in numerous studies as a risk factor for readmissions and 
was found to be significantly associated with readmission in most studies (Table 2). Notably, 
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even small differences in the MELD score are associated with a higher risk for readmission, 
though no cutoff point can be discerned. In addition, this association is seen regardless 
whether the MELD score is assessed at index admission or discharge. Several studies did not 
report the absolute differences in the MELD score listed in Table 2, but did find associations 
between increased MELD score and readmission in adjusted models.16,20,27,34 One study 
found that a higher MELD score was associated with decreased readmissions over 6 months, 
but this study did not account for the competing risk of death.37
DISCUSSION
Hospital readmission is a costly and common problem in the US.2 In addition to the negative 
impact that readmissions have on patients’ lives,40 readmissions are increasingly being used 
to measure quality. Unplanned 30-day readmissions are posted publicly, and excess 
readmissions for high-risk conditions are penalized through HRRP.3 Although HRRP does 
not currently include cirrhosis, the program has expanded to include several conditions that 
were not included in the initial iteration. Whether cirrhosis will be included in future 
iterations remains to be seen; however, increasing scrutiny is likely to continue. Of specific 
populations at risk, patients with cirrhosis are particularly vulnerable due to several features. 
Ascites management often requires hospitalization due to diuretic titration and poor access 
to paracentesis, and hepatic encephalopathy treatment requires complex lactulose titration.16 
Other features of cirrhosis, such as gastrointestinal bleeding, infections, and renal failure, 
also place patients at risk of poor outcomes. The resulting readmission burden is high, with a 
pooled 30-day readmission rate of 26%. Other associated outcomes are also poor, with a 
consistent relationship between readmission and subsequent mortality.
We found striking heterogeneity in various aspects. First, the inclusion/exclusion criteria 
varied widely, both cirrhosis-specific (eg, spontaneous bacterial peritonitis) and more 
general (patients admitted within the prior 30 days). Some of these criteria may bias 
readmission estimates; the risk of readmission may be reduced in those on hospice, as 
patients forgo curative therapy. Additionally, an established risk factor for readmission is 
prior hospitalization41; excluding patients with prior admissions prohibits analysis of this 
variable. Another aspect is the capture of readmissions: readmissions outside of the index 
hospital were not included in most studies. In those that did include outside readmissions, 
the burden was sizeable: 17% in 1 single-center study and 23% in a multistate administrative 
database.16,36 These outside readmissions must be included in future studies; they are as 
important as same-center readmissions both to patients and CMS.3 Despite this 
heterogeneity, the studies scored relatively high on the Newcastle–Ottawa risk of bias scale, 
with the only common deficiency being an inadequate description of follow-up.
Building on the findings of this review, an important step will be the design of interventions 
to reduce readmissions. Such interventions require a full understanding of this population’s 
characteristics and needs. Critically, we found a lack of data on social determinants of 
health. Impairments in these factors are well-established contributors to readmission risk in 
other populations,4,40 and are highly prevalent in cirrhosis.42 Indeed, CMS has focused 
resources toward social determinants of health in the effort to reduce utilization and improve 
outcomes. This lack of data on social determinants of health, as well as other understudied 
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factors, represents an important opportunity for future research efforts to better define the 
modifiable features that could be targeted in the future to prevent readmissions. Such 
research is urgently needed and will likely require prospective studies to gather these 
important factors. Notably, most studies in this systematic review were retrospective and 
therefore unable to examine many of these understudied factors. Another important aspect 
that has received little attention is readmission preventability: only 2 studies assessed 
preventability, both through unstructured chart review. Preventability assessments in 
noncirrhotic populations have used wide-ranging methodologies, yielding inconsistent 
results.43 This variability prompted recommendations that preventability should be assessed 
by multiple reviewers guided by explicit parameters.43 Such detailed attention to 
preventability is urgently needed to better inform interventions.
In contrast to the lack of data on social factors, we found that the MELD score was 
examined in most studies and was frequently associated with readmission. Despite this 
consistent association, differences in the MELD scores between studies limit inferences into 
specific cutoff values that could identify the highest risk patients. Because of its existing 
widespread clinical use, the MELD score may prove to be important in readmission risk 
stratification. Efforts to develop a useful model including the MELD score are needed to 
target interventions to the highest risk patients.
This review has several limitations. Although we used a broad search strategy to capture 
studies, some may not have been included due to our selection criteria. For instance, 1 
retrospective paper described factors associated with high admission density during 1 year 
but did not specifically report the frequency of early readmissions.44 Similarly, a randomized 
trial of a disease management program did not specifically examine early readmissions.45 
Another quasi-experimental study of a quality improvement initiative was not included 
because a large proportion of their subjects was post liver transplant.46 However, the 
inclusion of these papers is unlikely to change our conclusions; the retrospective study 
identified factors similar to those in the included studies, and the quasi-experimental study 
overlapped with the included study that assessed frailty.27 Another potential limitation is the 
exclusion of studies published in abstract form only. Such studies may be important, as the 
field of cirrhosis readmissions is relatively young. However, including only full-paper 
publications ensures the inclusion of only higher quality studies scrutinized during the peer-
review process. Similarly, newer published studies may have been missed due to the 
abundant interest in this topic and ongoing research. Lastly, the significant heterogeneity of 
the studies limits conclusions that can be made regarding the pooled readmission rates.
In summary, we found that patients with cirrhosis experience a high incidence of hospital 
readmissions. Several processes of care may be associated with readmissions, suggesting 
room for improvement in caring for this population and reducing readmissions. However, we 
identified several gaps in the literature, which does not adequately describe social factors 
and is lacking details on readmission preventability assessment. Future studies should 
attempt to address these issues so that interventions can be targeted to the highest risk 
patients and designed to best meet the needs of patients with cirrhosis.
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FIG 1. 
Study flow.
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FIG 2. 
Forest plot of the proportion of patients with cirrhosis with a 30-day hospital readmission.
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